LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg)

Phase 1/2Completed

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diffuse Large B-cell Lymphoma

Conditions

Diffuse Large B-cell Lymphoma

Trial Timeline

Jan 1, 2011 → Feb 20, 2019

NCT ID

NCT02340936

About LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg)

LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg) is a phase 1/2 stage product being developed by Thermo Fisher Scientific for Diffuse Large B-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02340936. Target conditions include Diffuse Large B-cell Lymphoma.

What happened to similar drugs?

1 of 20 similar drugs in Diffuse Large B-cell Lymphoma were approved

Approved (1) Terminated (4) Active (15)

✅dabrafenib + trametinibNovartisApproved

🔄Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + GemcitabineAbbViePhase 3

🔄Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3

🔄acalabrutinib + placebo + Prednisone + Rituximab + Cyclophosphamide + Vincristine + DoxorubicinAstraZenecaPhase 3

🔄Zilovertamab vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Rituximab Biosimilar + Prednisone + Prednisolone + Vincristine + Rescue medicationMerckPhase 3

🔄Everolimus + Everolimus PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02340936	Phase 1/2	Completed	Jan 1, 2011	Feb 20, 2019	Diffuse Large B-cell Lymphoma

Competing Products

20 competing products in Diffuse Large B-cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
IVA337 + Placebo	Inventiva	Phase 2	29
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)	Eli Lilly	Phase 2	35
rituximab	Celltrion	Phase 1	21
YM155	Astellas Pharma	Phase 2	27
enzastaurin + gemcitabine + rituximab + oxaliplatin	Eli Lilly	Phase 2	35
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6	Johnson & Johnson	Phase 2	31
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine	Johnson & Johnson	Phase 2	35
Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine	AbbVie	Phase 3	47
ABBV-525	AbbVie	Phase 1	36
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab	AbbVie	Phase 1/2	36
Copanlisib + Venetoclax	AbbVie	Phase 1/2	36
Epcoritamab + Investigator's Choice Chemotherapy	AbbVie	Phase 3	44
Epcoritamab + Lenalidomide	AbbVie	Phase 2	39
Venetoclax + Selinexor	AbbVie	Phase 1	29
Epcoritamab	AbbVie	Phase 1	36
Loncastuximab Tesirine and Epcoritamab	AbbVie	Phase 2	42
Epcoritamab + Investigator's Choice Chemotherapy	AbbVie	Phase 3	44
bendamustine + navitoclax + rituximab	AbbVie	Phase 2	27
Epcoritamab	AbbVie	Phase 2	39
Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide	AbbVie	Phase 1/2	36